Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis
PLOS ONE · 25.04.2024 · 19 (4) · e0300809
DOI: 10.1371/journal.pone.0300809 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 25.04.2024. Verfasst von Luciano Adorini und 4 weiteren Autor:innen. Beteiligte Einrichtung: Intercept Pharmaceuticals, Inc., San Diego, California, United States of America. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Chenodeoxycholic Acid, Receptors, Cytoplasmic and Nuclear, Disease Models, Animal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intercept Pharmaceuticals.
Abstract (Originalsprache)
The nuclear farnesoid X receptor (FXR), a master regulator of bile acid and metabolic homeostasis, is a key target for treatment of nonalcoholic steatohepatitis (NASH). This study compared efficacy of FXR agonists obeticholic acid (OCA) and INT-787 by liver histopathology, plasma biomarkers of liver damage, and hepatic gene expression profiles in the Amylin liver NASH (AMLN) diet–induced and biopsy-confirmed Lep ob/ob mouse model of NASH. Lep ob/ob mice were fed the AMLN diet for 12 weeks before liver biopsy and subsequent treatment with vehicle, OCA, or INT-787 for 8 weeks. Hepatic steatosis, inflammation, and fibrosis (liver lipids, galectin-3, and collagen 1a1 [Col1a1], respectively), as well as plasma alanine transaminase (ALT) and aspartate transaminase (AST) levels, were assessed. Hepatic gene expression was assessed in Lep ob/ob mice that were fed the AMLN diet for 14 weeks then treated with vehicle, OCA, or INT-787 for 2 weeks. INT-787, which is equipotent to OCA but more hydrophilic, significantly reduced liver lipids, galectin-3, and Col1a1 compared with vehicle, and to a greater extent than OCA. INT-787 significantly reduced plasma ALT and AST levels, whereas OCA did not. INT-787 modulated a substantially greater number of genes associated with FXR signaling, lipid metabolism, and stellate cell activation relative to OCA in hepatic tissue. These findings demonstrate greater efficacy of INT-787 treatment compared with OCA in improving liver histopathology, decreasing liver enzyme levels, and enhancing gene regulation, suggesting superior clinical potential of INT-787 for the treatment of NASH and other chronic liver diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Intercept Pharmaceuticals, Inc., San Diego, California, United States of America.
- Gubra, Hørsholm, Denmark.
ORCID-Profile: Luciano Adorini, Mary Erickson
Förderung
- Intercept Pharmaceuticals
Zitieren
APA
Adorini, L., Rigbolt, K., Feigh, M., Roth, J., & Erickson, M. (2024). Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PLOS ONE, 19(4), e0300809. https://doi.org/10.1371/journal.pone.0300809
Vancouver
Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis. PLOS ONE. 2024;19(4):e0300809. doi:10.1371/journal.pone.0300809
BibTeX
@article{Adorini2024,
author = {Adorini, Luciano and Rigbolt, Kristoffer and Feigh, Michael and Roth, Jonathan and Erickson, Mary},
title = {Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {4},
pages = {e0300809},
doi = {10.1371/journal.pone.0300809}
}
EUVIMED